SyMRI 15 has been clinically validated in a large multi-center study across several prominent institutes in the United States. The results demonstrated that SyMRI 3D can replace conventional 3D imaging, enhancing both efficiency and throughput. In addition to its established capabilities in providing quantitative values and tissue segmentation, the findings reinforce its diagnostic accuracy, instilling confidence in users to substitute conventional 3D images with SyMRI T1 and T2 images.

"The approval in the UK represents a significant step in SyntheticMR's global expansion strategy and signifies strong potential for growth and increased market presence in Europe," said Ulrik Harrysson, CEO of SyntheticMR AB. "We are thrilled to announce that Version 15 of our 3D SyMRI solution is now available in the UK. This next generation of SyMRI 3D delivers unparalleled resolution and accuracy in brain imaging, transforming the field of medical diagnostics."